AURIS MEDICAL HOLDING news, videos and press releases
For more news please use our advanced search feature.
AURIS MEDICAL HOLDING - More news...
AURIS MEDICAL HOLDING - More news...
- Auris Medical Announces Launch of New Corporate Website
- Auris Medical Announces Publication of Data from Preclinical Studies with Bentrio™ Nasal Spray in Prevention and Mitigation of SARS-CoV-2
- Auris Medical to Develop KRAS-Targeting RNA Treatment for Colorectal Cancer as First Therapeutic Indication for OligoPhore™ Technology
- Auris Medical to Initiate Market Launch of Bentrio™ Nasal Spray in Germany
- Auris Medical Announces Significant Inhibition of Tumor Growth with OligoPhore siRNA Targeting NF-κB in Murine Model of Adult T-Cell Leukemia / Lymphoma
- Auris Medical Announces Acquisition of RNA Therapeutics Company and Plans for Strategic Repositioning
- Auris Medical Starts Preparations for Covid-19 Trial with Bentrio in India
- Auris Medical Holding to Present at LD Micro Invitational XI Conference
- Auris Medical Announces Completion of Bentrio Conformity Assessment Procedure for Marketing in EU
- Auris Medical Reaches Midpoint for Enrollment in Part B of AM-125 Phase 2 TRAVERS Trial in Acute Peripheral Vertigo
-
“The Buzz” Show: Auris Medical (NASDAQ: EARS) Provides Update on Bentrio Program in Allergy
- Auris Medical Provides Update on Bentrio Program in Allergy
- Auris Medical Announces Positive Preclinical and Clinical Outcomes with AM-301 and Details Plans for Market Launch
- Auris Medical to Provide Business Update on AM-301 Program on Tuesday, April 13, 2021
- Auris Medical Provides Business Update and Reports Second Half and Full Year 2020 Financial Results
- Auris Medical to Report Second Half and Full Year 2020 Financial Results and Provide Business Update on Wednesday, March 31, 2021
- Auris Medical Announces Initiation of Clinical Investigation of AM-301 in Allergic Rhinitis
- Auris Medical Provides Business Update
- Auris Medical Holding to Present at the 13th Annual LD Micro Main Event Conference
- Auris Medical Holding Ltd. Prices $8,000,000 Common Shares Offering Priced At-the-Market
- Auris Medical Reports Positive In vitro Efficacy Data for AM-301 in Protecting Against Sars-CoV-2 Infection
- Auris Medical Launches Website for AM-301-focused Subsidiary, Altamira Medica
- Auris Medical Announces Initiation of Part B of TRAVERS Phase 2 Study with AM-125 in Vertigo
-
Auris Medical - executive interview
- Auris Medical Provides Business Update and Reports First Half 2020 Financial Results
- Auris Medical to Report First Half 2020 Financial Results and Provide Business Update on Thursday, September 17, 2020
- Auris Medical Launches Development of Drug-Free Nasal Spray for Protection against Airborne Pathogens and Allergens
- Auris Medical Announces Positive Interim Data from TRAVERS Phase 2 Study with AM-125 in Vertigo
- Auris Medical Regains Listing Compliance with NASDAQ Minimum Bid Requirement
- Auris Medical Announces Completion of Enrollment into First Part of TRAVERS Phase 2 Study with AM-125 in Vertigo
